The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Allogeneic peripheral blood stem cell transplantation

동종 말초혈액조혈모세포이식

Min, Woo-Sung
민우성

  • Published : 20040000
⟨ Previous Next ⟩

Abstract

현재까지의 연구 결과에 따르면 동종 말초혈액조혈모세포이식의 경우 재발 위험성과 이식관련 사망 위험율이 높은 진행된 백혈병 환자의 경우에서만 동종 골수조혈모세포이식에 비해 우월한 성적을 보였다. 동종 말초혈액조혈모세포이식의 경우 이식편대숙주병의 발생이 상대적으로 높으며 T-세포제거에 의해 발생율은 감소시킬 수 있으나 이에따른 전체적인 이득은 아직 명확하지 않다. 타인 공여자로부터의 동종 말초혈액조혈모세포이식의 역할과 모범적 임상치료 계획은 향후 더 많은 경험과 보완연구가 필요하다.

Keywords

References

  1. RusselI NH, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral-blood stem-cells as an alternative to marrow for allogeneic transplantation (letter). Lancet 341:1482, 1993.
  2. Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W. Allogeneic granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation (letter). Blood 81:1404-1407, 1993
  3. Russell NH, Byrne JL. Allogeneic transplantation using peripheral blood stem cells. Best Pract Res Clin Haemtol 14:685-700, 2001. https://doi.org/10.1053/beha.2001.0167
  4. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, Pagliuca A, Cornelissen JJ, Schouten HC, Carrers E, Finke J, van Biezen A, Brand R, Niederwieser D, Gluckman E, de Witte TM; Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group. Retrospective comparison of bone marrow and granulocyte colony-stimulating factormobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99:4370-4378, 2002. https://doi.org/10.1182/blood.V99.12.4370
  5. 채의수, 전석봉, 성우진, 임종우, 김동환, 김종광, 박태인, 손상균, 서장수, 이규보. 동종 말초혈액조혈모세포이식에서 이식된 CD34+ 세포량에 따른 엄상적 결과. 대한혈 액학회지 38:24-31, 2003.
  6. 유건희, 민기운, 이수현, 성기웅, 김대원, 조은주, 구홍희. 소아의 HLA일치 동종말초혈조혈모세포이식. 대한소아혈액종양학회지 10:214-222, 2003.
  7. 권은희, 이남영, 이원길, 서장수 대용량 백혈구성분채집술을 통한 동종 말초혈액조혈모세포채집의 효과와 안정성. 대한수혈학회지 13:79-87, 2002.
  8. 곽동석, 이영택, 채의수, 서광운, 박성원, 백진호, 김종광, 김동환, 정진태, 박소향, 손상균, 서장수, 이규보. 악성혈액전환에서 GM-CSF($Leucogen^R$)를 기저로 가동화된 동종말초조혈모세포를 이용한 단기이식성적 보고. 대한혈액학회지 36:25-34, 2001.
  9. 김희제, 민우성, 박윤희, 김유진, 이석, 김동욱, 이종욱, 김춘추. 새로운 전처치법과 초대량의 CD34양성조혈모세포를 이용한 고 위험군 급성 골수성 백혈병 환자의 가족간 HLA 완전 일배체 불일치 이식. 대한내과학회지 65:81-89, 2003.
  10. 김희제, 민우성, 최수미. 이동건, 박윤희, 이종욱, 박종원, 김춘추. 고용량의 CD34 양성 조혈모세포와 새 전처치법을 이용한 급성골수성백혈병 환자의 혈연간 HLA 불일 치 동종이식. 대한혈액화회지 38.221-227, 2003.
  11. Kim HJ, Park CY, Park YB, Kim YJ, Kim DW, Min WS, Kim CC. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosup pression in severe aplastic anemia patients. Bone Marrow Transplant 31:79-86, 2003. https://doi.org/10.1038/sj.bmt.1703786
  12. Min CK, Kim DW, Lee JW, Han CW, Min WS, Kim CC. Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. Am J Hermtol 69:15-22, 2002. https://doi.org/10.1002/ajh.10015
  13. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A, Russell NH. Primary Transplantation of allogeneic peripheral-blood progenitor cells mobilized by Filgrastim (G-CSF). BIood 85:1666-1672, 1995.
  14. Bensinger WI, Weaver C, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD. Trans-plantation of allogeneic peripheral blood stem cells mobilised by recombinant human granulocylte colony-stimulating factor. Blood 85:1655-1658, 1995.
  15. Korbling M, Przepiorka D, Huh Y, 11. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson G, Kleine HD, Soong D, Deisseroth AB, Andreeff M, Champlin R. Allogeneic blood stem cell transplantation for refractory leukaemia and lymphoma: potential advantages of blood over marrow allograft. Blood 85:1659-1655, 1995.
  16. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Imroved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88:2775-2779, 1996.
  17. Storek J, Witherspoon R, Maloney D, Chauncey TR, Storb R. Improved reconstitution of CD4 cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow(letter). Blood 89:3891, 1997.
  18. Powles R, Mehya J, Kulkarni S, Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D, Horton C, Long S, Singhal S. Allogeneic blood and bone marrow stem cell transplantation in haematological malignant disease: a randomised trial. Lancet 355:1199-1200, 2000. https://doi.org/10.1016/S0140-6736(00)02080-8
  19. Trenschel R, Ross S, Husing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW, Runde V. Reduced risk of persisting cytomegalovirs pp65 anti genemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 25:665-672, 2000. https://doi.org/10.1038/sj.bmt.1702216
  20. Martinez C, Urbano-Ispizua A, Rozman C, Marin P, Rovira M, Sierra J, Montfort N, Carreras E, Montserrat E. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34(+) selected grafts with recipients of unmanipulated grafts. Exp Hematol 27:561-568, 1999. https://doi.org/10.1016/S0301-472X(98)00029-0
  21. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R, Solheim BG, Evensen SA. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 25:1129-1136, 2000. https://doi.org/10.1038/sj.bmt.1702422
  22. Vigorito A, Azevedo W, Marques JFC et al. Vigorito AC, Azevedo WM, Marques JFC, Azevedo AM, Eid KAB, Aranha FJP, Lorand-Metze I, Oliveira GB, Correa MEP, Reis ARC, Miranda ECM, de Souza CA. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematologial malignancies. Bone Marrow Transplant 22:1145-1151, 1998. https://doi.org/10.1038/sj.bmt.1701510
  23. Bensinger W, Martin P, Storer B, clift R, Forman SJ, Negrin R, Kashyap A, Flowers MED, Lilleby K, Chauncey TR, Storb R, Appelbaum FR. Trans plantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with mematologic cancers. N Engl J Med 344:175-181. 2001.
  24. Champlin H, Schmitz N, Horowitz M, Champlin RE, Schmitz N, Horowitz MM， Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr , Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringden O, Tomany SC, Rowlings PA, Van Hoef MEHM. Gratwohl A. for The IBMTR Histocom patibility and Stem Cell Sources Working Committee and The European Group. Blood stem cells compared with bone marrow as a source of haemopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem CeII Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95:3702-3709, 2000.
  25. CutlerC,GiriS, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analys. J Clin Oncol 19:3685-3691, 2001. https://doi.org/10.1200/JCO.2001.19.16.3685
  26. Solano C, Martinez C, Brunet S, Tomas JF, Urbano-Ispizua A, Zuazu J, Ojeda E, Bargay J, Moraleda JM, Bailen A, Sierra J, Garcia-Conde J, Rozman C. Chronic graft versus host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Bone Marrow Transplant 22:1129-1135, 1998. https://doi.org/10.1038/sj.bmt.1701500
  27. Majolino I, Saglio G, Scime R, Serra A, Cavallaro AM, Fiandaca T, Vasta S, Pampinella M, Catania P, Indovina A, Marceno R, Santoro A. High incidence qf chronic GVHD after primary allogeneic peripheral blood stem cell transplantation patients with hae-matological malignancies. Bone Marrow Transplant 17:555-560, 1996.
  28. Brown R, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF. Long-term follow up of high risk allogeneic peripheral blood stem cell transplant recipients: grqft versus host disease and transplant related mortality. J Clin Oncol 17:806-812, 1999. https://doi.org/10.1200/JCO.1999.17.3.806
  29. Blaise D, Kuentz M, Fortanier C, Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordiaoni P, Cahn JY, Boiron JM, Schuller MP, Moatti JP, Michallet M. Randomised trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukaemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 18:537-546, 2000. https://doi.org/10.1200/JCO.2000.18.3.537
  30. Miflin G, Russell NH, Franklin I, Cook G, Milligan DW, Hutchinson RM, Potter MN, Morgan GJ, Pagliuca A, Marsh J, Bell A. An analysis of the effect of chronic GVHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy 2:423-428, 2000. https://doi.org/10.1080/146532400539369
  31. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplan따tion Blood 98:1695-1700, 2001.
  32. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Jan KH, Shore TB, Walker IR, Browett P, Messner HA, Panzarella T, Lipton JH. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies for the Canadian Bone Marrow Transplant Group improved survival. Blood 100:1525-1531, 2002. https://doi.org/10.1182/blood-2002-01-0048
  33. Flowers MED, Parker PM, Johnston LJ, Matos AVB, Storer B, Bensinger WI, Storb R, Appelbaum FR, For man SJ, Blume KG, Martin PJ. Comparison of chronic graft versus host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100:415-419, 2002. https://doi.org/10.1182/blood-2002-01-0011
  34. Elmaagacli AB, Beelen DW, Opalka B, Seeber S, Schaefer UW. The risk of residual molecular and cyto genetic disease in patients with Philadelphia chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic blood stem cells compared with bone marrow. Blood 94:384-389, 1999.
  35. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JA, Good RA. T cell depletion of HLA-iden ticaI transplants in leukemia. Blood 78:2120-2130, 1991.
  36. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli M: Treattment of high-risk acute leukemia with T-cell-depleted stem cells from relapsed donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186-1193, 1998.
  37. Yamasaki S, Ohno Y, Taniguchi S, Yoshida T, Haya-shi S, Ogawa H, Shimazaki C, Takahashi S, Kasai M, Wake A, Nishimura M, Tokunaga K, Gondo H, Takaue Y, Harada M, Mineishi S. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies. Bone Marrow Transplant 33:279-289, 2004. https://doi.org/10.1038/sj.bmt.1704342
  38. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, Perez-Oteiza J, Ferra C, Zuazu J, Caballero D, Carvalhais A, Diez JL, Espigado I, Martinez C, Campilho F, Sanz MA, Sierra J, Garcia-Conde J, Montserrat E; Spanish Group for Allogenic Peripheral Blood Transplantation. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 97:383-387, 2001.
  39. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, post-transplant morbidity and rate of haermtological recovery after marrow transplants for haermatological maligooncy. BIood 88:3223-3229, 1996.
  40. Hale G & Waldmann H. Control of graft versus host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 13:597-611, 1994.
  41. Kottaridis P, Milligan D, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. In vivo CAMPATH-1H prevents graft versus host disease following non-myeloablative stem cell transplantation BIood 96:2419-2425, 2000.
  42. Cull G, Haynes A, Byrne J, Carter GI, Miflin G, Rebello P, Hale G, Waldmann H, Russell NH. Preliminary experience Of allogeneic stem cell transplantation for Iymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure related toxicity. Br J Haematol 108:754-760, 2000. https://doi.org/10.1046/j.1365-2141.2000.01879.x
  43. Arai S, Klingemann HG. Hematopoietic Stem Cell Transplantation: Bone Marrow vs. Mobilized Peripheral Blood. Archives of Medical Research 34:545-553, 2003. https://doi.org/10.1016/j.arcmed.2003.07.002
  44. Anderson D, DeFor T, Bums L,McGlave P, Miller J,Wagner J, Weisdorf D. A comparison of related donor peripheral blood and bone marrow transplants: importance of Iate-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant 9:52-59, 2003. https://doi.org/10.1053/bbmt.2003.50000
  45. Sierra J, Storer B, Hansen J, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukaemia: the effect qf leukaemic burden, donor HLA matching and marrow cell dose. Blood 89:4226-4235, 1997.
  46. Byrne J, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G, Waldmann H, Russell NH. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft versus host disease and outcome following unrelated donor transplantation for leukaemia. Bone Marrow Transplant 25:411-417, 2000. https://doi.org/10.1038/sj.bmt.1702165
  47. Ringden O , Remberger M, Runde V, Bornhauser M, Blau IW, Basara N. Holig K, Beelen DW, Hagglund H, Basu O , Ehninger G, Fauser AA. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 94:455-464, 1999.
  48. Remberger M, Ringden O , Blau IW, Ottinger H, Kremens B, Kiehl MG, Aschan J, Beelen DW, Basara N. Kumlien G, Gauser AA. Runde V. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98:1739-1745, 2001.
  49. Dey BR. McAfee SL. Colby C, Sackstein R. Saidman S, Tarbell N. Sachs DH, SykesM. Spitzer TR. Comparison of outcomes after transplantation of peripheral blood stem cells (PBSCT) versus bone marrow (BMT) following an identical non-myelooblative conditioning regimen (abstract). Blood 100:Suppl 1. 424a. 2002.
  50. Fujii N. Maeda Y, Takenaka K Shinagawa K. Imai T, Kozuka T. Ikeda K Sunami K. Hiramatsu Y, Ishimaru F. Niiya K. Harada M. Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyelooblative preparative regimen with cytarabine and cyclophosphamide: report of 2 cases. Int J Hematol 72:499-503, 2000.
  51. Pelus LM, Horowitz D. Cooper Sc. King AG. Peripheral blood stem cell mobilization A role for CXC chemokines. Crit Rev Oncol Hematol 43:257-275, 2002.
  52. Franklin I. Consensus conference on unrelated donor bone marrow transplantation: Royal College of Physicians of Edinburgh, October 29th and 30th, 1996. Blood 89:2226-2228, 1997.
  53. Borleffs JCC. Bosschaert M. Vrehen HM. Schneider MME, van Striijp J, Small MK. Barked KM. Effect of Escalating Doses of Recombinant Human Granuloyte Colony- Stimulating Factor (Filgrastim) on Circulating Neutrophils in Healthy Subjects. CLINICAL THERAPEUTICS@/VOL, 20, NO. 4, 1998.
  54. Stroncek D. Clay M. Herr G. Smith J, Ilstrup S, McCullough J. Blood counts in healthy donors 1 year after collection of granulocyte-colony-stimulating-factor-mobilised progenitor cells and the results of a second mobilisation and collection. Transfusion 37:304- 308, 1997.
  55. Cavallaro A. Lilleby K. Majolino I. Storb R. Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow up of normal donors who received recombinant human granulocyte colony stimulating factor. Bone Marrow Transplant 25:85-89, 2000.
  56. Anderlini P. Korbling M. Dale D. Anderlini P, Korbling M. Dale D. Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E. Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantion: considerations for donors. Blood 90:903-908, 1997.